NeOnc says Abu Dhabi health department clears IND for brain cancer drug NEO212

NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc.

NTHI

0.00
  • NeOnc Technologies won IND authorization from the Department of Health – Abu Dhabi for NEO212 in aggressive brain tumors, including glioblastoma.
  • Clearance marks NEO212’s first international regulatory nod, adding a non-US clinical path as the company engages the FDA on a registrational strategy.
  • The program follows a completed Phase 1 dose-escalation study that set 610 mg as the recommended Phase 2 dose.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606170918PRIMZONEFULLFEED9748523) on June 17, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.